2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2963 Single-cell mapping reveals a CSF1R therapeutic axis against aspergillosis after allo-HCT

Dalia Sheta, PhD, Zeinab Mokhtari2, Marlene Strobel3, Yidong YU4, Pia Wittmann5, Zahraa Abboud6, Anna M. Maria Arold7, Michael Kern8, Jorge Amich9, Nora Trinks10, Eslam Ibrahim11, Sebastian Reinhard12, Sina Hirsch13, Ivan Aleksic14, Vasileios Drosos15, Kerstin Günther16, knut Ohlsen17, Martin Fraunholz18, Christian Stigloher19, Albert-Garcia Garcia Lopez20, Sascha Schäuble21, Natalie E. Nieuwenhuizen22, Tobias Köhler23, Oliver Kurzai24, Emmanuel Saliba25, Panagiota Arampatzi26, Karl Sebastian Lang27, Alexander J Westermann28, Paul M. Jordan29, Oliver Werz30, Jürgen Löffler31, Gianni Panagiotou32, Hermann Einsele, MD, PhD33, Markus Sauer34, Katrin G. Heinze35, Manfred B. Lutz36, Heike M. Hermanns37, Ulrich Terpitz38, Andreas Beilhack39
1 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany, Faculty of Pharmacy, Mansoura University,, Mansoura, Egypt, Graduate School of Life Sciences (GSLS) Würzburg, Würzburg, Germany, Interdisciplinary Center for Clinical Research (IZKF), University Hospital Würzburg, Würzburg, Bayern, Germany
2 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany
3 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany, Graduate School of Life Sciences (GSLS) Würzburg, Würzburg, Germany
4 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany, Institute of Medical Mycology, Teikyo University, Teikyo, Japan
5 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany, Graduate School of Life Sciences (GSLS) Würzburg, Würzburg, Germany, Interdisciplinary Center for Clinical Research (IZKF), University Hospital Würzburg, Würzburg, Bayern, Germany
6 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany, Graduate School of Life Sciences (GSLS) Würzburg, Würzburg, Germany, Interdisciplinary Center for Clinical Research (IZKF), University Hospital Würzburg, Würzburg, Bayern, Germany
7 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany, Graduate School of Life Sciences (GSLS) Würzburg, Würzburg, Germany, Interdisciplinary Center for Clinical Research (IZKF), University Hospital Würzburg, Würzburg, Bayern, Germany
8 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany, Interdisciplinary Center for Clinical Research (IZKF), University Hospital Würzburg, Würzburg, Bayern, Germany
9 CIBER de Enfermedades Infecciosas (CIBERINFEC-CB21/13/00105), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain., Madrid, Spain, Laboratorio de Referencia e Investigación en Micología (LRIM), National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Majadahonda, 28220 Madrid, Spain., Madrid, Spain
10 Department of Biotechnology and Biophysics, Biocenter - Center for Integrative and Translational Bioimaging, Julius-Maximilians-Universität Würzburg, Würzburg, Germany, Graduate School of Life Sciences (GSLS) Würzburg, Würzburg, Germany
11 Institute for Molecular Infection Biology, University of Würzburg, Würzburg, Germany
12 Department of Biotechnology and Biophysics, Biocenter - Center for Integrative and Translational Bioimaging, Julius-Maximilians-Universität Würzburg, Würzburg, Germany, Graduate School of Life Sciences (GSLS) Würzburg, Würzburg, Germany
13 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany, Interdisciplinary Center for Clinical Research (IZKF), University Hospital Würzburg, Würzburg, Bayern, Germany
14 Department of Thoracic and Cardiovascular Surgery, University Hospital Würzburg, Würzburg, Germany
15 Department of Thoracic and Cardiovascular Surgery, University Hospital Würzburg, Würzburg, Germany
16 Department of Pharmaceutical/Medicinal Chemistry, Friedrich Schiller University, Jena, Germany
17 Institute for Molecular Infection Biology, University of Würzburg, Würzburg, Germany
18 Chair of Microbiology, Biocenter, Julius-Maximilians-University Würzburg, Würzburg, Germany
19 Imaging Core Facility of the Biocenter, Theodor-Boveri-Institute, Julius-Maximilians-Universität Würzburg (JMU), Würzburg, Bayern, Germany
20 Department of Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll Institute (Leibniz-HKI), Jena, Germany
21 Department of Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll Institute (Leibniz-HKI), Jena, Germany
22 Institute for Hygiene and Microbiology, Julius-Maximilians-Universität Würzburg (JMU), Würzburg, Germany
23 Institute for Hygiene and Microbiology, Julius-Maximilians-Universität Würzburg (JMU), Würzburg, Germany
24 Institute for Hygiene and Microbiology, Julius-Maximilians-Universität Würzburg (JMU), Würzburg, Germany
25 Helmholtz-Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for Infection Research (HZI), Würzburg, Germany
26 Core Unit Systems Medicine, University of Würzburg, Würzburg, Germany
27 Institute of Immunology, University Hospital Essen, University of Duisburg-Essen, Würzburg, Germany
28 Chair of Microbiology, Biocenter, Julius-Maximilians-University Würzburg, Würzburg, Germany, Cluster for Nucleic Acid Sciences and Technologies – NUCLEATE, Würzburg, Germany, Helmholtz-Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for Infection Research (HZI), Würzburg, Germany
29 Department of Pharmaceutical/Medicinal Chemistry, Friedrich Schiller University, Jena, Germany
30 Department of Pharmaceutical/Medicinal Chemistry, Friedrich Schiller University, Jena, Germany
31 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany
32 Cluster of Excellence Balance of the Microverse, Friedrich-Schiller-University, Jena, Germany, Department of Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll Institute (Leibniz-HKI), Jena, Germany, Faculty of Biological Sciences, Friedrich-Schiller-University, Jena, Germany
33 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany
34 Department of Biotechnology and Biophysics, Biocenter - Center for Integrative and Translational Bioimaging, Julius-Maximilians-Universität Würzburg, Würzburg, Germany
35 Rudolf-Virchow-Center, University of Würzburg, Würzburg, Germany
36 Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany
37 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany
38 Department of Biotechnology and Biophysics, Biocenter - Center for Integrative and Translational Bioimaging, Julius-Maximilians-Universität Würzburg, Würzburg, Germany
39 Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Bayern, Germany, Graduate School of Life Sciences (GSLS) Würzburg, Würzburg, Germany, Interdisciplinary Center for Clinical Research (IZKF), University Hospital Würzburg, Würzburg, Bayern, Germany

Background:
Invasive pulmonary aspergillosis (IPA) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Although neutropenia is considered a primary risk factor, the contribution of tissue-resident pulmonary immunity during early immune reconstitution remains poorly defined. We investigated the role of alveolar macrophages (AMs) in post-transplant antifungal defense and explored therapeutic AM modulation.

Methods:
Using a clinically relevant low-dose Aspergillus fumigatus infection model after allo-HCT, we investigated pulmonary host–pathogen interactions and antifungal responses using flow cytometry, advanced imaging, and functional assays. AM dependency was assessed using CD169-diphtheria toxin receptor (CD169-DTR) mice and independently validated by intratracheal clodronate-mediated AM depletion. Lung single-cell RNA sequencing (scRNA-seq) was used to define CSF1R expression patterns. The effects of M-CSF and IL-34 on AM function were evaluated in murine and primary human AMs.

Results:
AMs were the dominant antifungal effector population during early post-transplant immune recovery. Genetic AM depletion using CD169-DTR mice resulted in lethal A. fumigatus infection despite preserved neutrophil and monocyte recruitment. This finding was confirmed using clodronate-mediated AM depletion, demonstrating that AMs are non-redundant mediators of pulmonary antifungal protection.

Lung scRNA-seq revealed that CSF1R expression was highly enriched within the macrophage compartment and predominantly localized to AMs, identifying a specific therapeutic target. M-CSF, but not IL-34, enhanced AM antifungal activity by promoting migration, local proliferation, phagolysosomal maturation, and fungal killing while limiting inflammatory activation. These effects were conserved in primary human AMs. In vivo, M-CSF treatment restored early antifungal protection after allo-HCT, increased pulmonary AM recovery, preserved lung integrity, reduced inflammatory cytokines, and improved survival. AM depletion completely abrogated M-CSF-mediated protection.

Conclusions:
Our findings identify alveolar macrophages as essential gatekeepers of antifungal immunity after allo-HCT and reveal CSF1R-mediated AM reprogramming as a therapeutic strategy. M-CSF-driven activation of tissue-resident immunity may provide a novel approach to prevent lethal fungal infections during early immune recovery.

Andreas Beilhack: No relevant conflicts of interest to declare.